NCT00371345 - Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

May 31, 2009

Conditions

Breast CancerMetastasis

Interventions

DRUG

Dasatinib

Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average \<6 months)

DRUG

Dasatinib 100 mg

Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average \<6 months)

Trial Locations (23)

34

Local Institution, Lima

1000

Local Institution, Brussels

1019

Local Institution, Buenos Aires

1185

Local Institution, Buenos Aires

1200

Local Institution, Brussels

1684

Local Institution, Haedo

10461

Montefiore Medical Center, The Bronx

19111

Fox Chase Cancer Center, Philadelphia

21079

Local Institution, Dijon

25198

Local Institution, Lleida

28041

Local Institution, Madrid

31052

Local Institution, Toulouse

32224

Mayo Clinic Florida, Jacksonville

41100

Local Institution, Modena

44805

Local Institution, Saint-Herblain

75231

Local Institution, Paris

77030

University Of Texas Md Anderson Cancer Ctr, Houston

94143

Ucsf-Comprehensive Cancer Center, San Francisco

275997305

University Of North Carolina At Chapel Hill, Chapel Hill

02115

Dana-Farber Cancer Inst, Boston

Unknown

Local Institution, Arequipa

LIMA 11

Local Institution, Lima

08035

Local Institution, Barcelona